Published Research Summaries (click "Search" in Menu to filter)

This open label study examined the effectiveness of CBD isolate on kids diagnosed with different types of treatment-resistant focal epilepsy. It was published in the journal Epilepsia in July 2025.

There were 33 patients involved with an average age of 40, and 64% were women. Mood, anxiety, sleep, pain, and overall functioning were assessed. It was published in the Journal of Affective Disorders in July 2025.

Using nationally available data, this retrospective observational study looked for any correlation (positive or negative) with cannabis use and chronic pancreatitis outcomes. It was published in June 2025 in the Journal of Gastrointestinal and Liver Diseases.

This original research examined the effectiveness of a full-spectrum THC/CBD extract on chronic pain patients. It was published in the Journal of Pain and Palliative Care Pharmacotherapy in June 2025.

This study tested non-psychotropic CBD and CBDV against over 30 clinically relevant fungal pathogens, including Cryptococcus neoformans, a World Health Organization Critical Priority pathogen. It was published in the journal PLoS: Neglected Tropical Diseases in June 2025.

The non-psychoactive cannabinoid THCV has been reported to offer benefits for metabolic disorders such as diabetes and obesity through a variety of pathways. This study collected and analyzed existing research on the topic.

The data came from the NIS (National Inpatient Sample) database of hospital visits maintained by the Agency for Healthcare Research and Quality. Over 3.3 million Rheumatoid Arthritis patients from 2016 to 2021 were included.

Non-motor Parkinson's Disease symptoms can include cognitive impairment, sleep disturbances, autonomic dysfunction, anxiety and depression. It was published in the journal Frontiers in Human Neuroscience in February 2025.

"Medical marijuana was comparatively more effective than prescription medications for the treatment of chronic pain at 3 months" 

This program allowed children with certain types of epilepsy to be treated with purified cannabidiol, in the form of an approved CBD isolate, since standard treatments were ineffective. It was published in March 2025 in Epilepsy and Behavior Reports.

This study examined cannabis-based medicinal products' effectiveness in relieving pain specifically experienced by cancer patients. It was published in February 2025 in the Journal of Pain & Palliative Care Pharmacotherapy.

"the oral bioavailability can significantly vary based on the food intake, with a high-fat meal increasing the maximum concentration by fivefold." Also, vaporized CBD isolate had a much lower bioavailability than did CBD hemp flower.